Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 563Neoplasms 462Carcinoma, Non-Small-Cell Lung 422Prostatic Neoplasms 344Colorectal Neoplasms 325Lung Neoplasms 269Multiple Myeloma 235Neoplasm Metastasis 197Pancreatic Neoplasms 189Leukemia, Myeloid, Acute 187Ovarian Neoplasms 182Melanoma 153Squamous Cell Carcinoma of Head and Neck 143Head and Neck Neoplasms 121Recurrence 119Carcinoma, Renal Cell 119Carcinoma, Hepatocellular 119Stomach Neoplasms 116Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Glioblastoma 114Endometrial Neoplasms 114Lymphoma 113Brain Neoplasms 111Lymphoma, Non-Hodgkin 108Uterine Cervical Neoplasms 101Triple Negative Breast Neoplasms 99Hematologic Neoplasms 98Urinary Bladder Neoplasms 97Glioma 91Leukemia, Lymphocytic, Chronic, B-Cell 88

Interventions

trastuzumab deruxtecan 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unresectable Locally Recurrent Breast Cancer × 30 days × Clear all
NCT07497386 2026-05-11

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Recruiting
150 enrolled
Breast

Unresectable Locally Recurrent Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡